LINCOLN share price, P/E, ROE & financials

On 6 Nov 2026, Lincoln Pharmaceuticals was priced at ₹507.55, or 10.5× trailing earnings, against an industry P/E of 28.7×, and the shares are 34% below their 52-week high. Sales and net profit grew 9.5% and 6.4% a year over 3 years, with ROCE of 15% and ROE of 13%. It carries very little debt, and its dividend yield is 0.3%. It is a small-cap company with a market cap of ₹1,017 Cr, ranked 71st of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares fell 2.1% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Sep 2026.How we calculate this

past year

Open: ₹505.50
Day high: ₹513.45
Day low: ₹505.00
Prev. close: ₹512.55
Volume: 9.8K

Health check

2 good · 1 fair · 3 to check

ReturnsBehind
−2.1% over a year, better than 1 of 7 peers.
Price tagCheaper
P/E 10.5 vs industry 28.7.
GrowthSlow
Sales +9.5%, profit +6.4% a year over 3 years.
ProfitabilityAverage
ROCE 14.9% vs peer median 17.9%.
Balance sheetSolid
Practically debt-free, Piotroski 6 of 9.
Red flags1 to check
34% below its 52-week high.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹1,017 Cr, #71 of 154 in its industry by size.

Defensive

Beta 0.52 vs the NIFTY 50: moves less than the market.

Key metrics

Last 12 months to Sep 2026: sales ₹722 Cr · profit ₹97 Cr

Market cap: ₹1,017 Cr; Small cap
P/E: 10.5; Industry 28.7
Price to book: 1.25; Peers 4.99
Dividend yield: 0.35%
ROE: 12.7%; Peers 14.7%
ROCE: 14.9%; Peers 17.9%
Debt to equity: 0.00; Debt ₹3.42 Cr
EPS (TTM): ₹48.38; Face value ₹10
OPM (TTM): 13.2%; Net margin 13.4%
Sales growth: +17.1%; Latest quarter vs a year ago
Profit growth: +2.2%; Latest quarter vs a year ago
Price to sales: 1.41; EV/EBITDA 7.4

Strengths

Practically debt-free.
Quarterly sales up 17.1% on a year ago.
P/E of 10.5 against an industry P/E of 28.7.
Positive operating cash flow in each of the last 4 years.

Risks to check

34% below its 52-week high.

Derived automatically from reported figures. Not a recommendation.

About Lincoln Pharmaceuticals

Lincoln Pharmaceuticals Limited engages in manufacturing and trading of pharmaceutical products in India and internationally. The company offers products in the areas of anticold, antibiotic, otolaryngology, pain management, gastro, anti-malarial, anti-fungal, corticosteroids and cosmo-derma, anti-diabetic, anti-hypertensive, anti-infective, anti-bacterial, gynecology, cardio and CNS, respiratory system, and dyslipidemic; and branded generics in the form…

Headquarters: Ahmedabad
Employees: 1,352
Sector: Healthcare
ISIN: INE405C01035
Website: lincolnpharma.com

Price range

52 weeks

₹440.00₹770.00

Today

₹505.00₹513.45

Avg volume (3M): 57.7K
1-year return: minus 2.1%
From 52-week high: minus 34.1%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
LINCOLNLincoln Pharmaceuticals	507.55	minus 0.98%	1,017	10.5	1.25	14.9%	12.7%	14.6%	9.5%	6.4%	0.35%	minus 2.1%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
163	166	187	177	191
138	143	167	150	168
25.4	23.6	20.7	27.4	23.7
15.6%	14.2%	11.0%	15.5%	12.4%
7.2	15.1	0	24.3	9.5
0.2	0.3	0.3	0.3	0.3
3.6	3.7	3.7	3.9	3.9
28.8	34.7	16.7	47.6	29
30.6%	17.6%	30.3%	23.8%	29.6%
20	28.6	11.6	36.2	20.4
9.98	14.28	5.81	18.09	10.20

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +9.5%
Profit CAGR 3Y: +6.4%
EPS CAGR 3Y: +6.4%
ROE: 12.7%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
505	581	615	662
–	+15.0%	+6.0%	+7.6%
415	480	513	562
89.8	100	102	100
17.8%	17.3%	16.6%	15.1%
16.7	11.1	14.5	29.9
1.6	0.9	1	0.4
9.2	10.6	12.9	14.5
4.7	22.4	6.2	0.4
100	122	109	116
27.4%	23.7%	24.6%	24.0%
72.9	93.3	82.3	87.9
–	+28.0%	minus 11.7%	+6.7%
36.40	46.58	41.11	43.88

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
20	20	20	20
482	573	652	738
2	1.1	–	4.4
82.9	106	125	128
587	700	797	890
158	187	186	198
8.3	7.5	4.5	7.7
0	0	0	0.1
114	152	196	241
307	354	411	444
587	700	797	890

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
39.3	63.2	93	106
−36.6	−57.3	−78.9	−98.4
−4.5	−5.2	−6.4	0.2
−1.9	0.7	7.7	8.1
−14.3	−39.6	−19.2	−26
25	23.6	73.8	80.3
−3	−3	−3.6	−3.6

Shareholding pattern

Source: NSE filings

49.8%

promoters

Promoters49.78%
Public50.22%
As of 30 Sep 2026

Quarter	Promoters	Public	Promoter change
30 Sep 2026	49.78%	50.22%	0.00
30 Jun 2026	49.78%	50.22%	0.00
31 Mar 2026	49.78%	50.22%	0.00
31 Dec 2025	49.78%	50.22%	0.00
30 Sep 2025	49.78%	50.22%	–

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you